Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
An update on emerging drugs for Hodgkin lymphoma.
[hodgkin lymphoma, classical]
Most
patients
with
Hodgkin
lymphoma
(
HL
)
are
cured
with
modern
combined
modality
first
-line
treatments
.
Even
~
50
%
of
patients
with
relapsed
/
refractory
HL
can
be
cured
with
high
-dose
chemotherapy
(
HDCT
)
and
autologous
stem
cell
transplantation
.
However
,
chemotherapy
and
radiotherapy
cause
significant
acute
and
long
-term
side
effects
and
patients
relapsing
after
HDCT
have
a
dismal
prognosis
.
New
drugs
are
therefore
needed
to
reduce
the
toxicity
of
first
-line
treatments
and
to
increase
the
efficacy
of
relapse
treatments
.
Moreover
,
new
drugs
are
needed
for
the
treatment
of
older
patients
with
HL
because
results
with
current
treatments
are
disappointing
.
This
article
discusses
promising
new
drugs
for
the
treatment
of
classical
HL
that
have
been
evaluated
in
the
last
years
.
There
is
a
focus
on
the
antibody
drug
conjugate
brentuximab
vedotin
and
its
potential
for
the
future
treatment
of
HL
.
Moreover
,
data
on
the
histone
deacetylase
inhibitors
panobinostat
and
mocetinostat
,
the
mammalian
target
of
rapamycin
inhibitor
everolimus
,
the
Janus
kinase
2
inhibitor
SB
1518
and
the
immunomodulatory
agent
lenalidomide
are
summarized
.
Besides
improving
the
prognosis
of
relapsed
patients
,
new
drugs
should
be
used
to
replace
the
most
toxic
compounds
in
first
-line
therapy
to
reduce
acute
and
long
-term
toxicities
of
the
treatment
.
